Current Report Filing (8-k)
16 December 2021 - 10:02PM
Edgar (US Regulatory)
0001711933
false
0001711933
2021-12-15
2021-12-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 15, 2021
Akoya Biosciences, Inc.
(Exact name of registrant as specified in its
charter)
|
Delaware
|
001-40344
|
47-5586242
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
100 Campus Drive, 6th Floor
Marlborough, MA
(Address of principal executive offices)
|
01752
(Zip Code)
|
(855) 896-8401
(Registrant’s telephone number, including
area code)
Check the appropriate box below
if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
|
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
|
Common stock, par value $0.00001 per share
|
|
AKYA
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
|
Item 7.01
|
Regulation FD Disclosure.
|
On December 15, 2021, Akoya Biosciences, Inc. (the “Company”)
hosted an inaugural “Spatial Day” and presented slides which included a brief company overview (the “Company Overview”).
A copy of the slides comprising the Company Overview is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company
Overview may also be accessed under the “Investors” tab on the Company’s website at www.akoyabiosciences.com.
In accordance with General Instruction B.2 on Form 8-K, the information
set forth in this Item 7.01 and the Company Overview slides, attached to this report as Exhibit 99.1, are “furnished”
and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Please refer to Exhibit 99.1 for a discussion of certain forward-looking
statements included therein and the risk and uncertainties related thereto.
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Date:
December 15, 2021
|
Akoya
Biosciences, Inc.
|
|
|
|
|
|
|
By:
|
/s/
Brian McKelligon
|
|
|
|
Brian
McKelligon
|
|
|
|
Chief
Executive Officer
|
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2023 to Apr 2024
